Patients with nonsquamous non-small cell lung cancer are needed for a study to evaluate an experimental immunotherapy alone or in combination with chemotherapy

IRB/UVA Tracking #
Principal Investigator
Richard Hall
Lacey Botteon
Contact Phone
Official Trial Title
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have nonsquamous non-small cell lung cancer. The purpose of this study to evaluate an immunotherapy drug (pembrolizumab) alone or in combination with chemotherapy (carboplatin and pemetrexed) in patients with nonsquamous non-small cell lung cancer. The safety and effects of the experimental drug alone and in combination with chemotherapy will be evaluated for this study.

Participation includes 2 years maximum of the experimental drug treatment and possibly longer for chemotherapy treatment. After you finish your study treatment, your doctor will continue to follow your condition for a total of 5 years from when you began taking part in the study and watch you for side effects. The immunotherapy drug, pembrolizumab, and study specific test will be provided at no cost to you.

Additional information can be found here:


You will not receive compensation or reimbursement for participating in this study.